NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Azithromycin for Critical Asthma - Pediatrics

NCT06223828

RecruitingPhase 2, Phase 3

Sponsor: Johns Hopkins All Children's Hospital

Conditions: Pediatric Asthma, Critical Illness

Interventions: Azithromycin

Countries: United States

The CR-AZI Study will assess the immunomodulatory effects of Azithromycin for pediatric Critical Asthma.

Eligibility overview

Sex: ALL

Age: 3 Years to 17 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion criteria

* Age 3-17 years
* Admission to the PICU
* Primary diagnosis of critical asthma
* Prescription for continuous inhaled beta-agonist therapy and/or intravenous (IV) beta-agonist therapy
* Prescription for intravenous systemic corticosteroids

Exclusion criteria

* Critical Congenital Heart Disease Unrepaired
* Tracheostomy Dependence at Admission
* Ongoing Exposure to Azithromycin or Macrolide Antibiotics for any indication
* Past Medical History of Prolonged QT Syndrome or Arrhythmias
* Concomitant respiratory pathology including Acute Chest Syndrome, Interstitial Lung Disease, Cystic Fibrosis, and pulmonary hypertension

Locations (1)

St. Petersburg, Florida, United States